Prepared for: Shudarsana Company / Regulatory & Safety Stakeholders
Date: 15 October 2025 (content current as of 15 Oct 2025)
Sources: FDA, Reuters, WHO-related reporting, RAPS, Chemistry World, Reuters investigative archives, peer-reviewed summaries. Key sources cited inline.
Executive summary (key facts & numbers)
- In October 2025 Indian authorities and international agencies linked multiple children’s cough-and-cold syrups manufactured in India to acute toxic exposure from diethylene glycol (DEG) and, in some reports, ethylene glycol (EG). The affected brands named by Indian authorities include Coldrif (Sresan Pharmaceuticals), Re-Life Syrup (Shape Pharma) and Respifresh-TR (Rednex Pharmaceuticals); a fourth product (Dextromethorphan Hydrobromide Syrup by Kaysons Pharma) was recalled though India’s testing reportedly did not find DEG/EG. The U.S. FDA confirmed these products were not shipped to the U.S.. U.S. Food and Drug Administration+1
- Reported child fatalities in India from this outbreak vary across sources as authorities continued investigations while new cases were identified. Reuters and related reporting cite at least 17–23 child deaths in Madhya Pradesh linked to Coldrif and related products; subsequent reporting increased counts and arrests as investigations progressed (examples below). Reuters+1
- Laboratory testing reported extremely high contamination levels in at least one product: Coldrif tested at ~48.6% diethylene glycol (DEG) — nearly 500× the WHO/Indian acceptable limit of 0.1% for DEG in pharmaceutical glycerin/excipients. Other syrups showed lower but still unacceptable DEG contamination (e.g., Respifresh-TR ≈1.342%, ReLife ≈0.616% in reported tests). Reuters
- The World Health Organization issued alerts and urged national authorities to check for these batches and report any similar products because contaminated syrups can circulate via informal supply chains; WHO characterized this as a serious public-health risk and highlighted regulatory/testing gaps. RAPS+1
- This incident is the latest in a series of international poisonings (2012–2025) tied to DEG/EG contamination of liquid medicines manufactured in or traced to India — notable prior crises include the Gambia (≈66–70 child deaths, 2022) and Indonesia (≈99 child deaths, Oct 2022). Past events underline persistent supply-chain and quality-control vulnerabilities. Reuters+1
Background: DEG/EG contamination — why it kills
Diethylene glycol (DEG) and ethylene glycol (EG) are industrial glycols used in antifreeze and other industrial products. They are nephrotoxic and neurotoxic when ingested. Toxicity typically presents within hours–days with gastrointestinal symptoms (vomiting, abdominal pain), progressing to metabolic acidosis, acute kidney injury (oliguria/anuria), neurologic deterioration and possible death. Even small percentages of DEG/EG in syrups (far below 1%) can be lethal to infants and small children because of low body weight and repeat dosing. Regulatory limits for DEG in pharmaceutical excipients (e.g., glycerin) are typically in the parts-per-thousand to parts-per-million range (e.g., WHO/India limit commonly cited at 0.1%). U.S. Food and Drug Administration
Chronology & timeline (October 2025, focused)
- Early Oct 2025: Clusters of pediatric acute kidney injury and deaths detected in Chhindwara and surrounding districts of Madhya Pradesh, India. Clinical features (vomiting, oliguria, rapid progression to renal failure) prompted toxicology testing and epidemiologic investigation. (Local reporting & public-health alerts.) Reuters
- Tests & laboratory results: State drug control and independent labs tested samples of implicated syrups. Coldrif reportedly contained ~48.6% DEG (vastly above acceptable limits); Respifresh-TR and Re-Life had lower but positive DEG levels (~1.342% and ~0.616%, respectively). Authorities recalled implicated batches and suspended manufacturing at the implicated sites. Reuters+1
- Regulatory actions (India): Product recalls, bans on sale of named brands, halting of manufacturing at implicated plants, searches/raids of company premises, and arrests (including arrests of company officials and, in some reports, local prescribers or distributors). Indian authorities communicated with WHO and other national regulators. Reuters+1
- International response: The WHO issued alerts to member states to inspect supply chains and report if the affected products appeared in other markets; the U.S. FDA issued a public statement confirming no products entered the U.S. market and reminded manufacturers of existing testing guidances for glycerin (DEG testing guidance was issued 2023). U.S. Food and Drug Administration+1
Quantitative data (compiled from public reporting)
Table 1 — Key reported numeric facts (public sources)
| Item | Reported value / detail | Source |
|---|---|---|
| Reported child deaths (India, Oct 2025) | Reported range: at least 17 to 23+ (counts vary as investigations progress; some local reporting cites 19, 23). | Reuters, ChemistryWorld, other reporting. Reuters+1 |
| DEG concentration — Coldrif (Sresan) | ~48.6% (≈486,000 ppm) — ≈486× (or ~500×) the 0.1% (1,000 ppm) threshold commonly used for safety screening; this concentration is orders of magnitude lethal in pediatric dosing contexts. | Reuters testing reports. Reuters |
| DEG concentration — Respifresh-TR | ~1.342% (≈13,420 ppm) — >10× acceptable limit. | Reuters. Reuters |
| DEG concentration — Re-Life | ~0.616% (≈6,160 ppm) — >6× acceptable limit. | Reuters. Reuters |
| WHO alerts / Medical Product Alert | WHO issued an alert for the products and requested member-state vigilance. (WHO coordination cited by multiple outlets.) | RAPS / WHO-related reporting. RAPS |
| Historical deaths (Gambia, Oct 2022) | ≈66–70 reported child deaths linked to contaminated Indian syrups. | Reuters / WHO 2022 reporting. Reuters |
| Historical deaths (Indonesia, Oct 2022) | ≈99 reported child deaths in cluster associated with syrup/ liquid meds; led to temporary national syrup ban. | BBC / 2022 reporting. X (formerly Twitter) |
Notes on numbers: counts reported in fast-moving outbreaks are provisional; local surveillance may update totals as investigations progress and as case definitions are refined. Multiple news outlets report slightly different totals (17, 19, 23, 25) depending on when they published and whether they included probable vs confirmed deaths. Use the range reported by independent outlets and await official consolidated public-health reporting for final counts. Reuters+1
Laboratory & supply-chain failures — probable mechanisms
Based on public investigations of similar historic outbreaks (2022) and current reporting, the likely pathways include:
- Contaminated raw excipient (glycerin or propylene glycol) — substitution or contamination of pharmaceutical-grade glycerin with industrial or improperly tested glycerin containing DEG/EG. Past incidents (Gambia/Indonesia) traced contamination back to untested or adulterated glycerin sources. Reuters+1
- Inadequate vendor qualification and testing — either manufacturer failure to verify excipient certificates of analysis, or falsified documentation. WHO and investigative reporting have repeatedly highlighted gaps in supplier oversight. Reuters+1
- Laboratory/regulatory lapses — delayed or insufficient in-country testing capacity, inconsistent sampling, or interference with sampling/testing (allegations in prior incidents). These systemic weaknesses allow toxic products to reach the market before detection. Reuters
Regulatory responses & policy implications
Indian authorities
- Declared products toxic, ordered recalls, directed halts to manufacturing at implicated sites, and initiated criminal investigations (arrests). Authorities have said affected products were not exported to other countries per initial communications but cautioned about informal circulation. Reuters+1
WHO
- Issued medical product alerts and advised members to check national supplies, report detections, and remove suspect batches. WHO highlighted a “regulatory gap” for domestically marketed products in India and urged stronger surveillance and testing. RAPS+1
FDA (U.S.)
- Issued a public statement confirming none of the named products were shipped to the U.S., reminded manufacturers to follow testing guidance for glycerin and other excipients (noting a 2023 FDA guidance on testing glycerin for DEG), and encouraged vigilance across supply chains. U.S. Food and Drug Administration
Global regulatory impact
- Expect increased scrutiny on glycerin/solvent sourcing, expanded batch testing for DEG/EG (including for products intended for domestic use), and possible import/export controls or temporary market suspensions in importing countries if suspect products are found. Historical precedent (Indonesia 2022) shows countries may temporarily ban syrup products as a precaution. X (formerly Twitter)+1
Public-health impact & clinical considerations
- High pediatric vulnerability: small body mass and frequent dosing of antitussives/OTC syrups mean that even diluted contamination can cause rapidly progressive acute kidney injury (AKI) and death. Clinical presentation often begins with non-specific GI symptoms (vomiting, diarrhea) followed by oliguria and metabolic derangements; rapid diagnosis requires high suspicion and communication between clinicians and public-health labs. U.S. Food and Drug Administration
- Healthcare burden: affected regions require emergency dialysis capacity (pediatric), toxicology support, and surveillance — resources that may be limited in rural settings, worsening outcomes. Reuters
- Trust & behavior: repeated incidents erode public trust in essential medicines, risk reduced care-seeking, and may drive informal/counterfeit product use, further complicating surveillance and control.
Lessons learned from prior outbreaks (2022 onward)
- DEG/EG contamination recurred across multiple geographies (Gambia, Indonesia, Uzbekistan, 2022–2023) and was repeatedly linked to poor excipient quality control and gaps in regulatory oversight. These events led to improved WHO alerts and some national policy changes, but vulnerabilities persist — especially for locally sold products that may bypass export QC checks. Reuters+1
- Testing & supplier due diligence are effective mitigations — where regulators required more rigorous raw-material testing and supply-chain traceability, subsequent incidents were reduced. However, implementation varies by manufacturer and regulator. Reuters
Recommendations (for regulators, manufacturers, purchasers, clinicians)
Regulators
- Mandate routine DEG/EG screening for all glycerin and related excipient batches used in oral/paediatric products — not just for exports but for domestic distribution. Cite/extend FDA 2023 glycerin testing guidance as baseline. U.S. Food and Drug Administration
- Institute batch traceability and public registries for high-risk excipients.
- Rapidly publish consolidated case counts and analytical results to reduce uncertainty.
Manufacturers
- Implement multi-laboratory confirmatory testing for critical excipients (certificate of analysis alone is insufficient).
- Strengthen supplier audits, chain-of-custody documentation, and change-control processes.
- Immediately quarantine and test retained batches if any quality concerns arise.
Procurement & healthcare systems
- Prefer suppliers with documented third-party testing and global GMP recognition.
- Maintain emergency pediatric dialysis capacity and toxicology protocols in areas with high OTC syrup use.
Clinicians & public
- High index of suspicion for unexplained pediatric AKI with preceding cough-syrup use — report suspicious cases to public-health authorities and pharmacovigilance systems (e.g., India’s PV program, WHO).
- For parents: avoid giving OTC syrups to infants/children under guidance; seek medical attention if symptoms like severe vomiting, decreased urine output occur after medication use. U.S. Food and Drug Administration
Data gaps & uncertainties
- Final consolidated death counts and laboratory confirmation for every reported fatal case were not available at the time of writing; numbers reported by media differ as investigations are active. Use official public-health releases for definitive totals when they are published. Reuters
- Origin of contamination (adulteration vs supplier contamination vs deliberate substitution) remains under criminal and regulatory investigation; publicly available findings may take weeks–months to conclude.
Appendix A — Selected primary sources (representative)
- FDA — “FDA’s actions to protect children from contaminated cough medicine” (10 Oct 2025). U.S. Food and Drug Administration
- Reuters — “India declares three cough syrups toxic after child deaths” (9 Oct 2025) and follow-up reporting. Reuters+1
- RAPS / WHO reporting — “WHO raises alert over DEG-contaminated cough syrups” (Oct 2025). RAPS
- Chemistry World / other press summaries on reported fatalities and investigations. chemistryworld.com
- Historical coverage: Reuters / BBC coverage of 2022 Gambia & Indonesia incidents (for historical comparisons). Reuters+1
Short conclusion
The October 2025 cluster of pediatric deaths tied to DEG/EG-contaminated cough syrups in India is a severe, but sadly familiar, public-health event that exposes persistent vulnerabilities in global pharmaceutical supply chains — especially with respect to excipient quality control and domestic regulatory surveillance. The extremely high DEG level reported in at least one product (≈48.6%) indicates catastrophic product adulteration or contamination and explains the rapid, lethal clinical course observed in children. This incident should trigger immediate, coordinated action across manufacturers, national regulators, and international agencies to mandate routine excipient testing, strengthen supply-chain oversight, and protect children from preventable toxic exposures.
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.